孤立性肺腺癌血流模式定量CT参数相互关系的初步研究

被引：10

作者：

李慎江

肖湘生

刘士远

李惠民

李成洲

张沉石

陶志伟

机构：

[1] 第二军医大学附属长征医院放射科

[2] 第二军医大学附属长征医院放射科上海

[3] 上海

来源：

放射学实践 | 2003年 / 04期

关键词：

肺腺癌; 血流模式; 体层摄影术,X线计算机; 定量; 参数;

D O I：

10.13609/j.cnki.1000-0313.2003.04.025

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

目的 :探讨孤立性肺腺癌血流模式定量CT参数相互关系 ,以便设计简便的扫描程序研究肺腺癌血管生成。方法 :2 9例孤立性肺腺癌 (直径≤ 4cm)患者行多层螺旋CT(MSCT)动态增强 (以 4ml/s的流率注入对比剂 90ml)。记录孤立性肺腺癌的定量参数 (强化值、肺腺癌主动脉强化值比、灌注量和平均通过时间 )。用线性回归分析评价主动脉强化值与孤立性肺结节的参数及各参数间的关系 ,并经逐步回归建立参数间的回归方程。结果 :肺腺癌强化值 (PHBA)为(36 .86± 1 3 .0 6)HU ,与动脉强化值 (PHA)呈正相关 (r =0 .586 ,P =0 .0 0 1 ) ,肺腺癌与大动脉强化值比 (BA to Aratio)为1 5 .58± 4 .52及灌注值 (PBA)为 (32 .2 7± 1 1 .75)ml/ (min·1 0 0g)与动脉强化值无显著相关 (r=0 .0 0 0 1 ,P >0 .0 5 ;r=0 .0 86 ,P >0 .0 5) ,肺腺癌灌注值与强化值及肺腺癌与大动脉强化值比呈正相关 (r =0 .437,P <0 .0 5 ;r=0 .468,P <0 .0 5) ,肺腺癌强化值与肺腺癌与大动脉强化值比呈正相关 (r =0 .80 1 ,P <0 .0 0 1 ) ,平均通过时间 (1 7.2 7± 4 .60 )s,PBA=1 3 .2 93 +1 .2 1 8·BA to Aratio ,BA to Aratio=5 .371 +0 .2 77·PHBA。结论 :可用二元一次方程式表示肺腺癌灌注值、强化值及肺腺癌与大动脉强化值比的线性关系 ,

引用

页码：283 / 285

页数：3

共 13 条

[1]

Cancer[P]. 英国专利:GB0005466D0,2000-04-26

[2]

Folkman J,Beckner K,Angiogenesis imaging. Academic Radiology . 2000

[3]

What is evidence that tumors are angiogenesis dependent?. Folkman J. Journal of the National Cancer Institute . 1990

[4]

Angiogenesis and nonsmall cell lung cancer. Cox G,Jones JL,Walker RA,et al. Lung Cancer . 2000

[5]

Fujie T et al Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Yano T,Tanikawa S. European Journal of Cancer . 2000

[6]

Application of CTin the investigation of angiogenesis in oncology. Kennneth AM,Chusilp CharnsangaVej,Fred TL. Academic Radiology . 2000

[7]

Subsecond multi-slice computed tomography: basics and applications. Klingenbeck RK,Schaller S,Flohr T,et al. European Journal of Radiology . 1999

[8]

Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Keith RL,Miller YE,Gemmill RM,et al. Clinical Cancer Research . 2000

[9]

AdTIMP-2 inhibits tumor growth,angiogenesis, and metastasis, and prolongs survival in mice. Li H,Lindenmeyer F,Grenet C,et al. Human Gene Therapy . 2001

[10]

Vascular endothelial growth factor,platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. O′Byrne KJ,Koukourakis MI,Giatromanolaki A,et al. British Journal of Cancer . 2000

← 1 2 →